Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neurofibromatoses × cabozantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 19 Prostatic Neoplasms 11 Neoplasm Metastasis 11 Carcinoma, Hepatocellular 8 Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Breast Neoplasms 4 Pancreatic Neoplasms 3 Colorectal Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Multiple Myeloma 2 Melanoma 2 Liver Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Medullary 2 Brain Neoplasms 2 Adenocarcinoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Pheochromocytoma 1 Paraganglioma, Extra-Adrenal 1 Paraganglioma 1

Interventions

Surveys and Questionnaires 2 tipifarnib 1 pirfenidone 1 nilotinib 1 diphenylcyclopropenone 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sirolimus 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Magnetic Resonance Spectroscopy 1 Lidocaine 1 Imatinib Mesylate 1 Glycopyrrolate 1 Dexmedetomidine 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed

45 enrolled 10 charts

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡